Thirteen-year experience in lung transplantation for emphysema

Area of Science:

• Pulmonary Medicine
• Transplant Surgery
• Genetics

Background:

• Emphysema is a leading reason for lung transplantation.
• Patients are typically younger with alpha-1 antitrypsin deficiency (AAD) or older with chronic obstructive pulmonary disease (COPD).
• This study compares outcomes between AAD and COPD recipients.

Purpose of the Study:

• To analyze lung transplant outcomes for emphysema.
• To identify differences in mortality and morbidity between AAD and COPD recipients.
• To determine factors predicting mortality after lung transplantation for emphysema.

Main Methods:

• Retrospective analysis of 306 lung transplants for emphysema (1988-2000).
• Comparison of outcomes between 86 alpha-1 antitrypsin deficiency (AAD) recipients and 220 chronic obstructive pulmonary disease (COPD) recipients.
• Average follow-up of 3.7 years.

Main Results:

• Mean age of AAD recipients (49 years) was lower than COPD recipients (55 years).
• Hospital mortality was 6.2% with no difference between AAD and COPD groups.
• Five-year survival was similar for AAD (60.5%) and COPD (56.8%) recipients.
• Bilateral lung transplants showed better 5-year survival (66.7%) than single lung transplants (44.9%).
• Independent predictors of mortality included single lung transplantation and need for cardiopulmonary bypass.

Conclusions:

• Younger age of AAD recipients does not translate to superior survival compared to COPD recipients.
• Bilateral lung transplantation improves long-term survival for emphysema patients.
• Improved perioperative care and accumulated experience likely contributed to better survival rates over time.